SARS-CoV-2 coinfection in patients with invasive pulmonary aspergillosis: clinical characteristics and prognosis

Abstract Background COVID-19 associated pulmonary aspergillosis (CAPA) has been globally reported to be a life-threatening complication of severe COVID-19. Previous studies primarily focused on an association between secondary Aspergillus infection and elevated mortality risk in COVID-19 patients, w...

Full description

Saved in:
Bibliographic Details
Main Authors: Mengshu Xie, Xiaofeng Zhu, Ao Ma, Jiaqi Fan, Guangru Fei, Qianqian Zhou, Yan Zhang, Huimei Wu, Xuqin Jiang
Format: Article
Language:English
Published: BMC 2025-06-01
Series:Annals of Clinical Microbiology and Antimicrobials
Subjects:
Online Access:https://doi.org/10.1186/s12941-025-00805-8
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850207272203976704
author Mengshu Xie
Xiaofeng Zhu
Ao Ma
Jiaqi Fan
Guangru Fei
Qianqian Zhou
Yan Zhang
Huimei Wu
Xuqin Jiang
author_facet Mengshu Xie
Xiaofeng Zhu
Ao Ma
Jiaqi Fan
Guangru Fei
Qianqian Zhou
Yan Zhang
Huimei Wu
Xuqin Jiang
author_sort Mengshu Xie
collection DOAJ
description Abstract Background COVID-19 associated pulmonary aspergillosis (CAPA) has been globally reported to be a life-threatening complication of severe COVID-19. Previous studies primarily focused on an association between secondary Aspergillus infection and elevated mortality risk in COVID-19 patients, while potential confounding factors and alternative pathogenic mechanisms remain insufficiently investigated. The risk factors and outcomes of patients with secondary SARS-CoV-2 infection following invasive pulmonary aspergillosis (IPA) were not been well explored either. Methods This retrospective monocentric study enrolled 152 hospitalized IPA patients with and without SARS-CoV-2 infection from 1 November 2022 to 31 October 2023. The characteristics of IPA patients and related risk factors were investigated, and the relationship between different SARS-CoV-2 infection status and the prognosis in IPA patients was further evaluated. Results Our analysis demonstrated that IPA patients subsequently diagnosed with SARS-CoV-2 infection exhibited significantly elevated mortality risk compared to those without viral coinfection (53.6% vs. 22.9%, P < 0.001). SARS-CoV-2 infection status (OR 3.708; P = 0.001; 95%CI 1.674–8.212), albumin concentration (OR 0.885; P = 0.005; 95%CI 0.813–0.964), and C-reactive protein level (OR 1.007; P = 0.012; 95%CI 1.002–1.013) were statistically significant independent risk factors for prognosis of IPA patients. Subsequent analysis established a multivariate risk prediction model incorporating independent prognostic factors, which exhibited robust discriminative capacity for mortality risk stratification via ROC curve validation (AUC = 0.792, 95%CI 0.721–0.862, P < 0.0001). A statistically significant difference in mortality rate existed between IPA patients with secondary SARS-CoV-2 infection and CAPA patients (63.2% and 33.3%, P = 0.037). Notably, comparative analysis revealed no statistically significant differences in 28-day (22/96, 22.9% vs. 6/18, 33.3%) or 90-day mortality rates (22/96, 22.9% vs. 6/18, 33.3%) between patients with IPA without SARS-CoV-2 infection and IPA patients with secondary SARS-CoV-2 infection. Conclusions IPA patients with secondary SARS-CoV-2 coinfection had a lower mortality compared to those with CAPA. Considering the high mortality rate, more medical cares are needed for these patients.
format Article
id doaj-art-c3c56a2438eb445f9db9e1fdf7e97633
institution OA Journals
issn 1476-0711
language English
publishDate 2025-06-01
publisher BMC
record_format Article
series Annals of Clinical Microbiology and Antimicrobials
spelling doaj-art-c3c56a2438eb445f9db9e1fdf7e976332025-08-20T02:10:34ZengBMCAnnals of Clinical Microbiology and Antimicrobials1476-07112025-06-0124111110.1186/s12941-025-00805-8SARS-CoV-2 coinfection in patients with invasive pulmonary aspergillosis: clinical characteristics and prognosisMengshu Xie0Xiaofeng Zhu1Ao Ma2Jiaqi Fan3Guangru Fei4Qianqian Zhou5Yan Zhang6Huimei Wu7Xuqin Jiang8Department of Pulmonary Medicine, School of Clinical Medicine, Bengbu Medical UniversityDepartment of Pulmonary Medicine, School of Clinical Medicine, Bengbu Medical UniversityDepartment of Pulmonary Medicine, School of Clinical Medicine, Bengbu Medical UniversityDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of ChinaDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of ChinaDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of ChinaSchool of Health Service Management, Anhui Medical UniversityAnhui Geriatric Institute, Department of Geriatric Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical UniversityDepartment of Pulmonary Medicine, School of Clinical Medicine, Bengbu Medical UniversityAbstract Background COVID-19 associated pulmonary aspergillosis (CAPA) has been globally reported to be a life-threatening complication of severe COVID-19. Previous studies primarily focused on an association between secondary Aspergillus infection and elevated mortality risk in COVID-19 patients, while potential confounding factors and alternative pathogenic mechanisms remain insufficiently investigated. The risk factors and outcomes of patients with secondary SARS-CoV-2 infection following invasive pulmonary aspergillosis (IPA) were not been well explored either. Methods This retrospective monocentric study enrolled 152 hospitalized IPA patients with and without SARS-CoV-2 infection from 1 November 2022 to 31 October 2023. The characteristics of IPA patients and related risk factors were investigated, and the relationship between different SARS-CoV-2 infection status and the prognosis in IPA patients was further evaluated. Results Our analysis demonstrated that IPA patients subsequently diagnosed with SARS-CoV-2 infection exhibited significantly elevated mortality risk compared to those without viral coinfection (53.6% vs. 22.9%, P < 0.001). SARS-CoV-2 infection status (OR 3.708; P = 0.001; 95%CI 1.674–8.212), albumin concentration (OR 0.885; P = 0.005; 95%CI 0.813–0.964), and C-reactive protein level (OR 1.007; P = 0.012; 95%CI 1.002–1.013) were statistically significant independent risk factors for prognosis of IPA patients. Subsequent analysis established a multivariate risk prediction model incorporating independent prognostic factors, which exhibited robust discriminative capacity for mortality risk stratification via ROC curve validation (AUC = 0.792, 95%CI 0.721–0.862, P < 0.0001). A statistically significant difference in mortality rate existed between IPA patients with secondary SARS-CoV-2 infection and CAPA patients (63.2% and 33.3%, P = 0.037). Notably, comparative analysis revealed no statistically significant differences in 28-day (22/96, 22.9% vs. 6/18, 33.3%) or 90-day mortality rates (22/96, 22.9% vs. 6/18, 33.3%) between patients with IPA without SARS-CoV-2 infection and IPA patients with secondary SARS-CoV-2 infection. Conclusions IPA patients with secondary SARS-CoV-2 coinfection had a lower mortality compared to those with CAPA. Considering the high mortality rate, more medical cares are needed for these patients.https://doi.org/10.1186/s12941-025-00805-8COVID-19COVID-19 associated pulmonary aspergillosis (CAPA)Invasive pulmonary aspergillosis (IPA)Secondary SARS-CoV-2 infectionRisk factor
spellingShingle Mengshu Xie
Xiaofeng Zhu
Ao Ma
Jiaqi Fan
Guangru Fei
Qianqian Zhou
Yan Zhang
Huimei Wu
Xuqin Jiang
SARS-CoV-2 coinfection in patients with invasive pulmonary aspergillosis: clinical characteristics and prognosis
Annals of Clinical Microbiology and Antimicrobials
COVID-19
COVID-19 associated pulmonary aspergillosis (CAPA)
Invasive pulmonary aspergillosis (IPA)
Secondary SARS-CoV-2 infection
Risk factor
title SARS-CoV-2 coinfection in patients with invasive pulmonary aspergillosis: clinical characteristics and prognosis
title_full SARS-CoV-2 coinfection in patients with invasive pulmonary aspergillosis: clinical characteristics and prognosis
title_fullStr SARS-CoV-2 coinfection in patients with invasive pulmonary aspergillosis: clinical characteristics and prognosis
title_full_unstemmed SARS-CoV-2 coinfection in patients with invasive pulmonary aspergillosis: clinical characteristics and prognosis
title_short SARS-CoV-2 coinfection in patients with invasive pulmonary aspergillosis: clinical characteristics and prognosis
title_sort sars cov 2 coinfection in patients with invasive pulmonary aspergillosis clinical characteristics and prognosis
topic COVID-19
COVID-19 associated pulmonary aspergillosis (CAPA)
Invasive pulmonary aspergillosis (IPA)
Secondary SARS-CoV-2 infection
Risk factor
url https://doi.org/10.1186/s12941-025-00805-8
work_keys_str_mv AT mengshuxie sarscov2coinfectioninpatientswithinvasivepulmonaryaspergillosisclinicalcharacteristicsandprognosis
AT xiaofengzhu sarscov2coinfectioninpatientswithinvasivepulmonaryaspergillosisclinicalcharacteristicsandprognosis
AT aoma sarscov2coinfectioninpatientswithinvasivepulmonaryaspergillosisclinicalcharacteristicsandprognosis
AT jiaqifan sarscov2coinfectioninpatientswithinvasivepulmonaryaspergillosisclinicalcharacteristicsandprognosis
AT guangrufei sarscov2coinfectioninpatientswithinvasivepulmonaryaspergillosisclinicalcharacteristicsandprognosis
AT qianqianzhou sarscov2coinfectioninpatientswithinvasivepulmonaryaspergillosisclinicalcharacteristicsandprognosis
AT yanzhang sarscov2coinfectioninpatientswithinvasivepulmonaryaspergillosisclinicalcharacteristicsandprognosis
AT huimeiwu sarscov2coinfectioninpatientswithinvasivepulmonaryaspergillosisclinicalcharacteristicsandprognosis
AT xuqinjiang sarscov2coinfectioninpatientswithinvasivepulmonaryaspergillosisclinicalcharacteristicsandprognosis